Aripiprazole

Drug Profile

Aripiprazole

Alternative Names: Abilify; Abilify Maintena; Abilitat; Ao Pai; Aripiprazole depot formulation - Otsuka Pharmaceutical/Lundbeck; Aripiprazole ECER tablets; Arlemide; OPC-14597; OPC-14597 IMD; OPC-31

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer Bristol-Myers Squibb; Indiana University; Lundbeck A/S; Otsuka Pharmaceutical
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Mood stabilisers; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Dopamine D2 receptor partial agonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor antagonists; Histamine H1 receptor antagonists; Serotonin 1A receptor partial agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor partial agonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Autistic disorder; Bipolar disorders; Gilles de la Tourette's syndrome; Major depressive disorder; Schizophrenia
  • Phase III Agitation; Pervasive child development disorders
  • Discontinued Attention-deficit hyperactivity disorder; Psychotic disorders

Most Recent Events

  • 28 Jul 2017 Registered for Bipolar disorders (Monotherapy) in USA (IM)
  • 14 Jun 2017 Otsuka Pharmaceutical and Lundbeck A/S initiates enrolment in a phase I trial for Schizophrenia in USA (IM) (NCT03150771)
  • 23 May 2017 US FDA accepts NDA for aripiprazole drug-device combination single tablet for Schizophrenia, Bipolar I disorders and Major depressive disorder (Adjunctive treatment) for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top